EAGLE, Idaho, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it expects to issue its third quarter 2025 financial results on Wednesday, November 5, 2025.
Pennant invites current and prospective investors to tune into a live webcast to be held the following day, Thursday, November 6, 2025, at 10:00 a.m. Mountain Time (12:00 p.m. Eastern Time), during which Pennant’s management will discuss its third quarter results.
To listen to the webcast, or to view any financial or other statistical information required by SEC Regulation G, please visit the Investor Relations section of our website at http://investor.pennantgroup.com. The webcast will be recorded and will be available for replay via the website until 5:00 p.m. Mountain Time on November 6, 2026.
About Pennant
The Pennant Group, Inc. is a holding company of independent operating subsidiaries that provide healthcare services through home health and hospice agencies and senior living communities located throughout Alabama, Arizona, California, Colorado, Georgia, Idaho, Montana, Nevada, Oklahoma, Oregon, Tennessee, Texas, Utah, Washington, Wisconsin and Wyoming. Each of these businesses is operated by a separate, independent operating subsidiary that has its own management, employees and assets. More information about Pennant is available at www.pennantgroup.com.
Contact
The Pennant Group, Inc.
(208) 401-1400
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$29.34 |
| Daily Change: | -0.02 -0.07 |
| Daily Volume: | 251,466 |
| Market Cap: | US$1.010B |
November 05, 2025 November 04, 2025 October 02, 2025 September 03, 2025 August 06, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
